PharmaVoice
JUNE 30, 2022
As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.
Pharmacy Is Right For Me
JUNE 29, 2022
There are so many different types of careers within the field of pharmacy—from research and drug development to pharmacy informatics! To highlight some of the more unique career settings in the industry, we’re introducing a new page on our website— Novel Pharmacy Practice Settings —where you can explore these unique career pathways. In addition to learning more about unique pathways on our new webpage, we’ll also be featuring pharmacists who work in these unique settings on our blog.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NY Times
JUNE 28, 2022
With Roe v. Wade overturned, states banning abortion are looking to prevent the distribution of abortion medication. Brazil shows the possible consequences.
Pharmaceutical Technology
JUNE 29, 2022
Approximately 75,000 enzymes are thought to exist in the human body as vital catalysts for biochemical reactions or conversions. For hundreds of years, we have found myriad uses for microbial enzymes in manufacturing – from food, drink, and household products to a range of industrial applications. The pharmaceutical industry often relies on enzymes to perform a process known as biocatalysis, which facilitates the cost-effective and sustainable production of small molecule drugs at scale.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PharmaVoice
JUNE 27, 2022
The CEO of SaNOtize is tapping into outside-the-box innovation to develop a nitric oxide-delivery platform to treat and prevent COVID-19.
pharmaphorum
JUNE 27, 2022
An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a “functional cure” for the widespread disease. Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks’ treatment to below the lower limit of detection in people with chronic hepatitis B, raising hopes
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharmaceutical Technology
JULY 1, 2022
The latest issue of Pharma Technology Focus is out now. Read it for free on all devices. Some months after the first Covid-19 vaccines became available, the World Health Organization (WHO) set a target of vaccinating 70% of each country’s population by the end of June 2022. Global trends indicate that initially, a slow supply did not allow African countries, in particular, to stay on pace to meet this target, and now vaccination rates have even begun to slow down.
PharmaVoice
JUNE 29, 2022
The two Penn Medicine researchers whose work brought the mRNA vaccines into COVID-19 fruition want to see the pharma world embrace early science.
pharmaphorum
JUNE 30, 2022
The FDA’s decision not to approve Spero Therapeutics’ oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic resistance, according to a GlobalData analyst. The FDA delivered a blow to Spero’s hopes of bringing the carbapenem to market in a complete response letter (CRL) delivered this week, which said another trial would be required to support approval.
European Pharmaceutical Review
JULY 1, 2022
A recent paper outlines a process that can be used to select and document worst-case sampling locations to validate cleaning processes. The article, published in the Journal of Validation Technology ( JVT ), presents the case study of a company undergoing an investigation and developing a strategy for identifying worst-case sampling locations on equipment, after a regulatory auditor asked for such a rationale and no written documentation could be provided.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmaceutical Technology
JUNE 29, 2022
The proportion of pharmaceutical companies hiring for AI related positions kept relatively steady in May 2022 compared with the equivalent month last year, with 39.3% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 39% of companies who were hiring for AI related jobs a year ago but a decrease compared to the figure of 43.6% in April 2022.
PharmaVoice
JUNE 29, 2022
How the chief commercial officer and president of innovative medicines international plans to fuel growth and productivity at the company.
pharmaphorum
JUNE 30, 2022
Merck & Co is looking for startup companies applying artificial intelligence , machine-learning and other digital approaches to drug discovery and development for a new accelerator programme. The big pharma – known as MSD outside North America – is initially offering support to 12 companies though the newly-formed Merck Digital Sciences Studio (MDSS) and is now taking applications from would-be participants.
European Pharmaceutical Review
JUNE 27, 2022
Sickle cell disease – a rare, yet prevalent, genetic disease in Europe. Sickle cell disease (SCD) is a devastating, lifelong blood disorder that occurs when someone inherits sickle cell genes from both parents. 1 It affects haemoglobin, a protein carried by red blood cells that delivers oxygen throughout the body. 2 SCD predominantly affects those whose ancestors are from sub-Saharan Africa but is also common in people of Hispanic, South Asian, Southern European and Middle Eastern ancestry. 3 Wh
Pharmaceutical Technology
JULY 1, 2022
Pfizer has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for Paxlovid (nirmatrelvir tablets and ritonavir tablets) to treat Covid-19 patients at increased disease progression risk. An inhibitor of SARS-CoV-2 main protease (Mpro), Paxlovid is intended to be given orally. Due to the oral form, the therapy can be prescribed in the early infection stage to avert severe illness.
PharmaVoice
JUNE 28, 2022
The hormonal and genetic test developed by Adyn is designed to predict and prevent adverse birth control side effects.
pharmaphorum
JUNE 27, 2022
Almost half (48%) of cancer clinical trials in the US have no Hispanic or Latin American subjects, and 42% have no black patients, according to a diversity analysis focusing on thousands of studies conducted in the past 15 years. The analysis – from a dataset that spans more than half a million patients – reveals once again the lack of inclusivity in clinical research, which undermines the ability of clinical trials to generate results that reflect the real-world situation in US cancer treatmen
European Pharmaceutical Review
JUNE 27, 2022
DRUG DEVELOPMENT based on targeted protein degradation (TPD) has progressed rapidly since the publication in 2015 of three landmark papers 1-3 that highlighted important early-stage breakthroughs with drug-like molecules in this area of research. Since that time, the field has advanced to the point where there are now more than two dozen companies dedicated to working on the development of TPD drugs, some of which have advanced to later-stage clinical development.
Pharmaceutical Technology
JUNE 29, 2022
Terumo Blood and Cell Technologies and BioBridge Global subsidiary, GenCure, have entered a new partnership agreement to expand and integrate cell and gene therapy manufacturing solutions. In a bid to meet the growing demand for automated and closed smart systems across the cell and gene therapy (CGT) industry, the companies entered the deal to merge technologies and capabilities.
PharmaVoice
JUNE 28, 2022
A new report from IQVIA reveals the current challenges — and promise — in cancer drug R&D.
pharmaphorum
JUNE 29, 2022
Bayer has stepped up the digital capabilities of its radiology business with the launch of artificial intelligence-based apps for X-ray, MRI and CT imaging. The cloud-hosted platform – called Calantic Digital Solutions – has tools to help radiologists detect and quantify disease lesions in medical images and select patients for treatment in order of priority, improving their productivity.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for AIRDUO+RESPICLICK Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are sixteen…. The post New patent for Teva Pharm drug AIRDUO RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Technology
JUNE 28, 2022
Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule. It can potentially enhance the anti-cancer effect.
PharmaVoice
JUNE 27, 2022
The downturn shows few signs of hurting large pharma, but small biotechs and generics makers could face a credit crunch.
PharmExec
JUNE 29, 2022
As director of corporate strategy for Novartis, Kamenska defines direction for the company’s overall enterprise. Here, she discusses how the pandemic and recent market events are shaping these strategies.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for LICART Licart is a drug marketed by Ibsa Inst Bio and is included in one NDA. The generic ingredient in LICART is diclofenac epolamine. Additional…. The post New patent for Ibsa Inst drug LICART appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Technology
JUNE 27, 2022
Last Friday, the World Health Organization (WHO) launched updated guidelines for the treatment of hepatitis C , calling for testing and treatment to be delivered in peripheral and community-based facilities and integrating these with available care services. While some countries are making progress in eliminating hepatitis C, many remain challenged in reaching those affected, Dr Philippa Easterbrook, Senior Scientist at WHO’s Department of Global HIV, Hepatitis and Sexually Transmitted Infection
PharmaVoice
JUNE 29, 2022
The latest personnel changes from around the industry.
Pharmaceutical Commerce
JUNE 28, 2022
Amy Shortman outlines some ways visibility technology is solving problems at a time when it’s needed most, and how digitization is the key to overcoming supply chain crises.
Drug Patent Watch
JUNE 30, 2022
Annual Drug Patent Expirations for LUSEDRA Lusedra is a drug marketed by Eisai Inc and is included in one NDA. There is one patent protecting this drug. This drug has…. The post New patent expiration for Eisai Inc drug LUSEDRA appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Technology
JUNE 27, 2022
Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for its CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel) to treat relapsed or refractory large B-cell lymphoma (LBCL) in adult patients. Breyanzi is given as a defined composition for reducing the variability of the CD8 and CD4 component dose.
pharmaphorum
JUNE 27, 2022
The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued at a little under $250 million. Ipsen is offering $1.45 per share for Cambridge, Massachusetts-based Epizyme – valuing the US company at around $247 million – and is also promising a further contingent value right (CVR) payment of up to $1 per share if Tazverik (tazemetostat) achieves certain development and sales targets.
European Pharmaceutical Review
JUNE 27, 2022
Europe’s Healthier Together initiative. The European Commission (EC) has launched the Healthier Together: EU Non-communicable diseases (NCDs) initiative to support EU Member States in reducing the burden of NCDs by addressing the leading causes of avoidable premature death in Europe and improving citizens’ health and well-being. The €156 million initiative identifies effective actions and the available legal and financial supporting tools across five main areas: cardiovascular diseases, di
Drug Patent Watch
JUNE 29, 2022
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are seven…. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Technology
JUNE 30, 2022
Pfizer and BioNTech have entered a new vaccine supply agreement worth $3.2bn with the US government to supply further doses of their Covid-19 vaccine. As per the agreement, the government will procure 105 million 3µg, 10 µg and 30 µg doses of the vaccine. This deal might comprise Omicron-adapted Covid-19 vaccines for use in adults, contingent on obtaining the US Food and Drug Administration (FDA) authorisation.
Expert insights. Personalized for you.
336 
Let's personalize your content